BCDA vs ADMA vs GRFS vs MCRB vs TAK

For growth investors, ADMA Biologics, Inc.

(ADMA) is the stronger pick with 19. 6% revenue growth year-over-year, versus -87. 8% for BioCardia, Inc. (BCDA). Seres Therapeutics, Inc. (MCRB) offers the better valuation at 12. 0x trailing P/E, making it the more compelling value choice. Analysts rate ADMA Biologics, Inc. (ADMA) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Seres Therapeutics, Inc.

(MCRB) is the cheapest at 12. 0x versus Takeda Pharmaceutical Company Limited at 76. 8x. On forward P/E, Takeda Pharmaceutical Company Limited is actually cheaper at 0. 2x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, ADMA Biologics, Inc.

(ADMA) delivered a total return of +389. 2%, compared to -99. 3% for BioCardia, Inc. (BCDA). Over 10 years, the gap is even starker: ADMA returned +34. 8% versus BCDA's -99. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Takeda Pharmaceutical Company Limited (TAK) is the lower-risk stock at 0.

33β versus Seres Therapeutics, Inc. 's 1. 73β — meaning MCRB is approximately 424% more volatile than TAK relative to the S&P 500. On balance sheet safety, ADMA Biologics, Inc. (ADMA) carries a lower debt/equity ratio of 17% versus 188% for Seres Therapeutics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), ADMA Biologics, Inc.

(ADMA) is pulling ahead at 19. 6% versus -87. 8% for BioCardia, Inc. (BCDA). On earnings-per-share growth, the picture is similar: Grifols, S. A. grew EPS 147. 8% year-over-year, compared to -26. 2% for Takeda Pharmaceutical Company Limited. Over a 3-year CAGR, ADMA leads at 49. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Seres Therapeutics, Inc.

(MCRB) is the more profitable company, earning 721. 9% net margin versus -137. 0% for BioCardia, Inc. — meaning it keeps 721. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ADMA leads at 37. 5% versus -137. 9% for BCDA. At the gross margin level — before operating expenses — TAK leads at 65. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Takeda Pharmaceutical Company Limited (TAK) trades at 0.

2x forward P/E versus 9. 7x for ADMA Biologics, Inc. — 9. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ADMA: 157. 0% to $21. 00.

In this comparison, TAK (3.

6% yield), GRFS (2. 6% yield) pay a dividend. BCDA, ADMA, MCRB do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Takeda Pharmaceutical Company Limited (TAK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

33), 3. 6% yield). Seres Therapeutics, Inc. (MCRB) carries a higher beta of 1. 73 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (TAK: -2. 1%, MCRB: -98. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: BCDA is a small-cap quality compounder stock; ADMA is a small-cap high-growth stock; GRFS is a small-cap deep-value stock; MCRB is a small-cap deep-value stock; TAK is a mid-cap income-oriented stock. GRFS, TAK pay a dividend while BCDA, ADMA, MCRB do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.